

**FINDING OF NO SIGNIFICANT IMPACT**

**for**

**ADSPEC™ (SPECTINOMYCIN SULFATE) STERILE  
SOLUTION FOR TREATMENT OF BOVINE  
RESPIRATORY DISEASE IN CATTLE**

**THE UPJOHN COMPANY  
KALAMAZOO, MI**

**FOR PUBLIC DISPLAY**

**FINDING OF NO SIGNIFICANT IMPACT**

for


**ADSPEC™ (SPECTINOMYCIN SULFATE) STERILE SOLUTION FOR  
TREATMENT OF BOVINE RESPIRATORY DISEASE IN CATTLE****THE UPJOHN COMPANY  
KALAMAZOO, MI**

The Center for Veterinary Medicine has considered the potential environmental impact of this action and has concluded that this action will not have a significant effect on the quality of the human environment and that an environmental impact statement therefore will not be prepared.

The Upjohn Company has submitted an NADA for the approval of ADSPEC™ (spectinomycin sulfate) sterile solution for treatment of bovine respiratory disease in cattle. The product will be administered to cattle under a veterinarian's order by subcutaneous injection in the neck at a dosage of 10 to 15 mg spectinomycin per kg of body weight. Treatment will be administered at 24-hour intervals for 3 to 5 consecutive days.

In support of this supplement, The Upjohn Company submitted an abbreviated environmental assessment (EA), dated May 29, 1996. The EA adequately addresses potential environmental impacts from the manufacture of bulk drug and finished product. We have reviewed the EA and determined that the proposed action is not expected to have a significant impact on the human environment.

11/13/96  
Date

  
Director, Office of New Animal Drug Evaluation, HFV-100

Attachment: Environmental Assessment, dated May 29, 1996